Skip to main content
. Author manuscript; available in PMC: 2024 Oct 1.
Published in final edited form as: Lancet Oncol. 2023 Oct;24(10):1147–1156. doi: 10.1016/S1470-2045(23)00403-5

Fig. 3. Cumulative incidence of SMN-related late-mortality among CPV carriers vs. non-carriers in SJLIFE (a); and CCSS (b).

Fig. 3

Note: There were 27 SJLIFE survivors and 49 CCSS survivors who died with unknown causes were excluded from the calculation of cumulative incidence of SMN-related mortality where other-cause deaths were treated as a competing risk.